TAC-GUCY2C

N/A

Report date: 2022/10/26 17:06:40

Base Information

Drug NameTAC-GUCY2C
Drug Alias NameTAC-GUCY2C
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionAnti-Heat-stable enterotoxin receptor
TargetsHeat-stable enterotoxin receptor
Therapy Area/IndicationsStomach NeoplasmsColorectal NeoplasmsEsophageal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTriumvira Immunologics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTriumvira Immunologics Inc
Inactive CompaniesN/A
Active IndicationsStomach NeoplasmsColorectal NeoplasmsEsophageal Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A